Routine bone marrow exam during first remission of acute myeloid leukemia

Blood

Volumn 87, Issue 9, 1996, Pages 3899-3902

  Estey, Elihu ^a,b   Pierce, Sherry ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLOOD CELL COUNT; BONE MARROW EXAMINATION; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 0029873601     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.9.3899.bloodjournal8793899     Document Type: Article

References (12)

1. Cheson B, Cassileth P, Schiffer C, Bennett J, Bloomfield C, Brunning R, Gale R, Grever M, Keating M, Sawitsky A, Stass S, Weinstein H, Woods W: Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia J Clin Oncol 8:813, 1990
2. Mayer R, Davis R, Schiffer C, Berg D, Powell B, Schulman P, Omura G, Moore J, McIntyre OR, Frei E for the Cancer and Leukemia Group B: Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 331:896, 1994
3. Cassileth P, Lynch E, Hines J, Oken M, Mazza J, Bennett J, McGlave P, Edelstein M, Harrington D, O'Connell M: Varying intensity of postremission therapy in acute myeloid leukemia. Blood 79:1924, 1992
4. Bishop J, Lowenthal R, Joshua D, Matthews J, Todd D, Cobcroft R, Whiteside M, Kronenberg H, Ma D, Dodds A, Herrmann R, Szer J, Wolf M, Young G for the Australian Leukemia Study Group: Etoposide in acute nonlymphocytic leukemia. Blood 75:27, 1990
5. Morrison F, Kopecky K, Head D, Athens J, Balcerzak S, Gumbart C, Dabich L, Costanzi J, Coltman C, Saiki J, Hussein K, Fabian C, Appelbaum F: Late intensification with POMP chemotherapy prolongs survival in acute myelogenous leukemia - results of a Southwest Oncology Group study of rubidazone versus adriamycin for remission induction, prophylactic intrathecal therapy, late intensification, and levamisole maintenance. Leukemia 6:708, 1992
6. Müller E, Sauter C: Routine bone marrow punctures during remission of acute myelogenous leukemia. Leukemia 6:419, 1992
7. Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O'Brien S, Esucdier S, Robertson L, Koller C, Kornblau S, Pierce S, Freireich E, Deisseroth A, Keating M: Use of G-CSF before, during, and after fludarabine + ara-C induction therapy of newly-diagnosed AML or MDS: Comparison with fludarabine + ara-C without G-CSF. J Clin Oncol 12:671, 1994
8. Sauter C, Fopp M, Imbach P, Tschopp L, Berchtold W, Gratwohl A, Maurice P, von Fliedner V: Acute myelgenous leukaemia: Maintenance chemotherapy after early consolidation treatment does not prolong survival. Lancet 1:379, 1994
9. Appelbaum F, Clift R, Buckner C, Stewart P, Storb R, Sullivan K, Thomas E: Allogeneic marrow transplantation for acute non-lymphoblastic leukemia after first relapse. Blood 61:949, 1983
10. Hiddemann W, Martin WR, Sauerland CM, Heinecke A, Büchner T: Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: A proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin in 150 patients with relapse after standardized first line therapy. Leukemia 4:184, 1990
11. Campana D, Pui CH: Detection of minimal residual disease in acute leukemia: Methodologic advances and clinical significance. Blood 85:1416, 1995
12. Miller W, Levine K, DeBlasio A, Frankel S, Dmitrovsky E, Warrell R: Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-α fusion mRNA. Blood 82:1689, 1993